-
2025-523347-35-00
11
2026-03-05
Atopic Dermatitis
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-522514-23-00
5
2026-02-12
Urinary Incontinence
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
-
2025-520464-17-00
4
2025-10-21
Atherosclerotic Cardiovascular disease
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-518914-18-00
4
2025-08-27
Moderate to Severely Active Ulcerative Colitis & Moderate to Severely
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-517529-26-00
5
2025-08-04
Chronic Inflammatory Demyelinating Polyneuropathy